By Fineline Cube 
China‑based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series D funding round, raising over RMB 400 million. The round was led jointly by IDG Capital, Shenzhen Capital Group (SCGC) and Ruipu Pharma, underscoring confidence in Maxvax’s pipeline and the growing demand for recombinant protein vaccines in both human and veterinary markets.
Capital Allocation and Strategic Focus
The newly raised capital will be directed toward:
| Program | Development Stage | Primary Objective |
|---|---|---|
| Recombinant shingles (herpes zoster) vaccine | Phase III | Commercial‐preparation and market entry. |
| Recombinant respiratory syncytial virus (RSV) vaccine | Phase III | Global safety & efficacy assessment. |
| Multiple innovative candidates | Pre‑clinical | Further research and international collaborative development. |
Maxvax’s commitment to public health is reflected in its plan to move from bench to bedside (and shelter) with a vertically integrated value chain that spans adjuvant R&D, formulation, and delivery systems.
Corporate Position and Capabilities
Maxvax Biotech’s proprietary platform combines adjuvant chemistry, recombinant protein technology, and immune‑evaluation assays. The company has:
- Developed ≈20 adjuvant raw materials and 3 mature delivery systems.
- Created 10+ composite formulations for both human and companion‑animal vaccines.
- Built an end‑to‑end value chain covering R&D, manufacturing, formulation, and clinical deployment.
With these assets, Maxvax is positioned to address both emerging infectious threats and chronic disease prevention on a global scale.
Investor and Market Implications
The Series D funding signals strong institutional support and positions Chengdu Maxvax to speed the delivery of its first two clinical candidate vaccines. Analysts will watch the company’s RSV and shingles trials for early safety signals and market potential, while the integrated supply chain may offer a competitive edge in vaccine manufacturing and logistics.-Fineline Info & Tech